Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I... Drugs R D (2018) 18:149–159 https://doi.org/10.1007/s40268-018-0236-x ORIGINAL RESEARCH ARTICLE Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers 1 1 1 2 • • • • Marie Cullberg Cecilia Arfvidsson Bengt Larsson Anna Malmgren 3 1 1 • • Patrick Mitchell Ulrika Wa ¨ hlby Hamre ´n Heather Wray Published online: 31 May 2018 The Author(s) 2018 Abstract Intra- and inter-subject variability in AUC was 3–11 and Objective The aim of this study was to summarise the 29–64%, respectively. Less than 5% of the AZD5069 dose pharmacokinetic findings from eight phase I studies in was excreted as parent drug in the urine. Elderly subjects healthy volunteers given oral AZD5069, a selective small- had 39% higher AZD5069 AUC and 21% higher C than max molecule CXCR2 antagonist. younger adults. Japanese subjects had similar or slightly Methods 240 healthy volunteers across eight phase I higher exposure to AZD5069 than Caucasian subjects. Co- studies received single (0.1–200 mg) or multiple once- or administration with ketoconazole resulted in 2.1-fold twice-daily (10–120 mg) oral AZD5069 as solution, sus- higher AUC and 1.6-fold higher C . All formulations had max pension, capsules or tablets. Pharmacokinetics were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs in R&D Springer Journals

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Loading next page...
 
/lp/springer_journal/pharmacokinetics-of-the-oral-selective-cxcr2-antagonist-azd5069-a-0AYPl3TyV0

References (19)

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
1174-5886
eISSN
1179-6901
DOI
10.1007/s40268-018-0236-x
pmid
29856004
Publisher site
See Article on Publisher Site

Abstract

Drugs R D (2018) 18:149–159 https://doi.org/10.1007/s40268-018-0236-x ORIGINAL RESEARCH ARTICLE Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers 1 1 1 2 • • • • Marie Cullberg Cecilia Arfvidsson Bengt Larsson Anna Malmgren 3 1 1 • • Patrick Mitchell Ulrika Wa ¨ hlby Hamre ´n Heather Wray Published online: 31 May 2018 The Author(s) 2018 Abstract Intra- and inter-subject variability in AUC was 3–11 and Objective The aim of this study was to summarise the 29–64%, respectively. Less than 5% of the AZD5069 dose pharmacokinetic findings from eight phase I studies in was excreted as parent drug in the urine. Elderly subjects healthy volunteers given oral AZD5069, a selective small- had 39% higher AZD5069 AUC and 21% higher C than max molecule CXCR2 antagonist. younger adults. Japanese subjects had similar or slightly Methods 240 healthy volunteers across eight phase I higher exposure to AZD5069 than Caucasian subjects. Co- studies received single (0.1–200 mg) or multiple once- or administration with ketoconazole resulted in 2.1-fold twice-daily (10–120 mg) oral AZD5069 as solution, sus- higher AUC and 1.6-fold higher C . All formulations had max pension, capsules or tablets. Pharmacokinetics were

Journal

Drugs in R&DSpringer Journals

Published: May 31, 2018

There are no references for this article.